Risk factors
Anika Therapeutics (ANIK) risk factors
Item 1A of every Anika Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
43 risks, 3 new, 1 dropped, 8 reworded since the prior year. Anika Therapeutics faces regulatory delays for its Hyalofast product following an FDA deficiency letter.
Filed Mar 03, 2026 - FY2024 10-K risk factors
41 risks. Revenue heavily relies on J&J MedTech, which accounted for 57% of 2024 revenue for Monovisc and Orthovisc.
Filed Mar 17, 2025